FdaApplication
NDA 208685
Identifiers
- fda_app_no: NDA208685
Properties
| Property | Value |
|---|---|
| applicant_name | PTC THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2017-02-09 |
Revenue by product
EMFLAZA
| Period | Revenue |
|---|---|
| Q2 2026 | $24.6M |
| Q1 2026 | $21.5M |
| Q3 2025 | $35.2M |
| Q2 2025 | $36.4M |
| Q1 2025 | $47.8M |
| Q3 2024 | $51.9M |
| Q2 2024 | $47.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EMFLAZA | DEFLAZACORT | 22.75MG/ML | SUSPENSION;ORAL |
1 product